How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.12. The firm had revenue of $0.63 million for the quarter, compared to analysts' expectations of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA) , CrowdStrike (CRWD) , Dynavax Technologies (DVAX) , Block (SQ) , Abbott Laboratories (ABT) , Alpine Immune Sciences (ALPN) , Advanced Micro Devices (AMD) , BioLineRx (BLRX) , Cognex (CGNX) and Micron Technology (MU) .

When did Ayala Pharmaceuticals IPO?

Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AYLA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.44
▼
$0.57
50-Day Range: $0.38
▼
$0.58
52-Week Range: $0.36
▼
$7.31

Volume: 137,700 shs
Average Volume: 76,300 shs
Market Capitalization: $7.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Ayala Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

AYLA Stock News Headlines

February 13, 2024 | investing.com

Ayala Pharmaceuticals (ADXS) Earnings Dates & Reports

December 21, 2023 | benzinga.com

Ayala Pharmaceuticals Stock (OTC:ADXS) Dividends: History, Yield and Dates

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 19, 2023 | finanznachrichten.de

Advaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete Merger

January 19, 2023 | bizjournals.com

Cancer treatment developers Ayala Pharmaceuticals and Advaxis complete merger

November 17, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

November 16, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

November 16, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 4, 2022 | msn.com

Recap: Ayala Pharmaceuticals Q3 Earnings

November 4, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 4, 2022 | finance.yahoo.com

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates

October 20, 2022 | markets.businessinsider.com

AutoZone To Rise Over 9%? Plus Roth Capital Slashes PT On This Stock By 96%

October 19, 2022 | msn.com

Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session

October 19, 2022 | baystreet.ca

Ayala, Advaxis Merge

October 19, 2022 | markets.businessinsider.com

Ayala Pharma, Advaxis Announce Merger - Quick Facts

October 19, 2022 | bizjournals.com

Cancer treatment developers Ayala Pharmaceuticals and Advaxis to merge

September 30, 2022 | bizjournals.com

Lab Notes: 4 early stage life sciences firms close financing deals; 2 drug candidates get Fast Track approval

September 29, 2022 | finance.yahoo.com

Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors

September 27, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors

August 24, 2022 | finance.yahoo.com

Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress

August 2, 2022 | bizjournals.com

Philadelphia-area life sciences companies with the largest stock, market cap declines in first half of 2022

July 27, 2022 | nasdaq.com

Ayala Pharmaceuticals Stock Nearly Triples on Twitter Post. Is it a Buy?

July 26, 2022 | nasdaq.com

Ayala Pharmaceuticals Stock Nearly Triples on Desmoid Tumor Treatment News

July 6, 2022 | finance.yahoo.com

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

July 5, 2022 | finance.yahoo.com

Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study

June 2, 2022 | finance.yahoo.com

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

See More Headlines

Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AYLA
CUSIP: N/A
CIK: 1797336
Web: www.ayalapharma.com
Phone: 857-444-0553
Fax: N/A
Employees: 35
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,250,000.00
Net Margins: -2,341.69%
Pretax Margin: -2,298.60%
Return on Equity: -182.13%
Return on Assets: -139.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.28
Quick Ratio: 2.28

Sales & Book Value

Annual Sales: $3.51 million
Price / Sales: 2.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.45 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 14,821,000
Free Float: 14,287,000
Market Cap: $7.46 million
Optionable: Not Optionable
Beta: 1.98

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Roni Mamluk M.D. (Age 55)
Ph.D., Pres, CEO & Director
Comp: $692.06k
Mr. Yossi Maimon CPA (Age 51)
CPA, M.B.A., MBA, CFO, Sec. & Treasurer
Comp: $556.43k
Dr. Gary B. Gordon M.D. (Age 69)
Ph.D., Chief Medical Officer
Comp: $577.4k
Dr. Shmuel Tuvia Ph.D.
Chief Scientific Officer
Ms. Irit Klipper Avni M.A.
VP of HR
Ms. Dana Gelbaum M.B.A. (Age 48)
M.Sc., Chief Bus. Officer

Key Competitors

View All Competitors

AYLA Stock Analysis - Frequently Asked Questions

How were Ayala Pharmaceuticals' earnings last quarter?: Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) released its earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.12. The firm had revenue of $0.63 million for the quarter, compared to analysts' expectations of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.
What other stocks do shareholders of Ayala Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Block (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).
When did Ayala Pharmaceuticals IPO?: Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

This page (NASDAQ:AYLA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)

AYLA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AYLA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info